Gene therapy approaches to ventricular tachyarrhythmias.

[1]  S. Lai,et al.  Targeted high-efficiency, homogeneous myocardial gene transfer. , 2007, Journal of molecular and cellular cardiology.

[2]  J. K. Donahue,et al.  Molecular ablation of ventricular tachycardia after myocardial infarction , 2006, Nature Medicine.

[3]  L. Couto,et al.  Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. , 2006, Blood.

[4]  W. Maisel,et al.  Pacemaker and ICD generator malfunctions: analysis of Food and Drug Administration annual reports. , 2006, JAMA.

[5]  A. Krahn,et al.  Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. , 2006, JAMA.

[6]  H. Stedman,et al.  Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. , 2005, Blood.

[7]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[8]  N. Iii.  Primary Prevention of Sudden Cardiac Death: A Rational Approach to the Use of the Implantable Cardioverter Defibrillator , 2005, Journal of Interventional Cardiac Electrophysiology.

[9]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[10]  Michael R Rosen,et al.  Expression and Function of a Biological Pacemaker in Canine Heart , 2003, Circulation.

[11]  E. Marbán,et al.  Gene therapy: Biological pacemaker created by gene transfer , 2002, Nature.

[12]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[13]  W. Stevenson,et al.  Catheter Ablation of Ventricular Tachycardia in Patients with Coronary Heart Disease Part II: Clinical Aspects, Limitations, and Recent Developments , 2001, Pacing and clinical electrophysiology : PACE.

[14]  E. Marbán,et al.  Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. , 2001, Journal of molecular and cellular cardiology.

[15]  E. Marbán,et al.  Focal modification of electrical conduction in the heart by viral gene transfer , 2000, Nature Medicine.

[16]  H. Calkins,et al.  Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multi Center Investigators Group. , 2000, Journal of the American College of Cardiology.

[17]  E. Marbán,et al.  Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin , 1998, Gene Therapy.

[18]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[19]  E. Marbán,et al.  Ultrarapid, highly efficient viral gene transfer to the heart. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[21]  S. Signoretti,et al.  Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. , 1996, Gene therapy.

[22]  L. Leinwand,et al.  Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Flotte,et al.  Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.